

DAFTAR PUSTAKA

- Abbas, A. K., Lichtman, A. H., & Pillai, S. (2007). Cellular and Molecular Immunology. (6th Edition). Philadelphia: Elsevier-Saunders.
- Aleem, A., Akbar Samad, A. B., & Vaqar, S. (2023). Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19). In StatPearls. StatPearls Publishing.
- Aslan, A., Aslan, C., Zolbanin, N. M., & Jafari, R. (2021). Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. *Pneumonia*, 13(1), 1-15.
- Atkins M. B. (2002). Interleukin-2: clinical applications. *Seminars in oncology*, 29(3 Suppl 7), 12–17. <https://doi.org/10.1053/sonc.2002.33077>
- Azwar, M. K., Setiati, S., Rizka, A., Fitriana, I., Saldi, S. R. F., & Safitri, E. D. (2020). Clinical Profile of Elderly Patients with COVID-19 hospitalised in Indonesia's National General Hospital. *Acta medica Indonesiana*, 52(3), 199–205.
- Bar-On, Y.M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi B, *et al.* (2021) Protection of BNT162b2 Vaccine *Booster* against Covid-19 in Israel. *N Engl J Med.* 2021 Oct 7;385(15):1393-1400. doi: 10.1056/NEJMoa2114255. Epub 2021 Sep 15. PMID: 34525275; PMCID: PMC8461568.
- Bellou, V., Tzoulaki, I., van Smeden, M., Moons, K. G., Evangelou, E., & Belbasis, L. (2022). Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis. *Eur J Respir*, 59(2): 2002964.
- Bhardwaj, A., Sapra, L., Saini, C., Azam, Z., Mishra, P. K., Verma, B., & Srivastava, R. K. (2022). COVID-19: immunology, immunopathogenesis and potential therapies. *International reviews of immunology*, 41(2), 171-206.
- Botta, M., Tsonas, A. M., Pillay, J., Boers, L. S., Algera, A. G., Bos, L. D. *et al.* (2021). Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study. *Lancet Respir Med*, 9: 139–48.
- Burhan, E., Susanto, A. D., Isbaniah, F., Nasution, S. A., Ginanjar, E., Pitoyo, C. W. *et al.* (2022). Pedoman Tatalaksana COVID-19 Edisi 4. Jakarta: Diterbitkan bersama oleh PDPI, PERKI, PAPDI, PERDATIN, IDAI.
- Marengoni, A., Zucchelli, A., Vetrano, D. L., Armellini, A., Botteri, E., Nicosia, F. *et al.* (2021). Beyond Chronological Age: Frailty and Multimorbidity Predict In-Hospital Mortality in Patients With Coronavirus Disease 2019. *The journals of gerontology*.

- Series A, Biological sciences and medical sciences*, 76(3), e38–e45.
<https://doi.org/10.1093/gerona/glaa291>
- Cevik, M., Bamford, C. C., & Ho, A. (2020). COVID-19 pandemic—a focused review for clinicians. *Clin Microbiol Infect*, 26: 842–7.
- Cevik, M., Kuppalli, K., Kindrachuk, J., & Peiris, M. (2020). Virology, transmission, and pathogenesis of SARS-CoV-2. *BMJ*, 371: m3862.
- Cevik, M., Marcus, J., Buckee, C., & Smith, T. (2021). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Dynamics Should Inform Policy. *Clin Infect Dis*, 73(2): S170–6.
- Cevik, M., Tate, M., Lloyd, O., Maraolo, A. E., Schafers, J., & Ho, A. (2021). SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe*, 2(1): e13–e22.
- Charitos, I. A., Ballini, A., Bottalico, L., Cantore, S., Passarelli, P. C., Inchingolo, F. *et al.* (2020). Special features of SARS-CoV-2 in daily practice. *World J. Clin. Cases*, 8: 3920–33.
- Cheng, H. Y., Jian, S. W., Liu, D. P., Ng, T. C., Huang, W. T., Lin, H. H., & Taiwan COVID-19 Outbreak Investigation Team (2020). Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA internal medicine*, 180(9), 1156–1163.
- Chida, D., & Iwakura, Y. (2007). Peripheral TNF α , but not peripheral IL-1, requires endogenous IL-1 or TNF α induction in the brain for the febrile response. *Biochemical and Biophysical Research Communications*, 364, 765–770.
- Cho, Y., Cho, Y., Choi, H. J., Lee, H., Lim, T. H., Kang, H., Ko, B. S. *et al.* (2021). The effect of BMI on COVID-19 outcomes among older patients in South Korea: a nationwide retrospective cohort study. *Annals of medicine*, 53(1), 1292–1301. <https://doi.org/10.1080/07853890.2021.1946587>
- Ciarambino T, Crispino P, Buono P, Giordano V, Trama U, Iodice V, *et al.* Efficacy and Safety of Vaccinations in Geriatric Patients: A Literature Review. *Vaccines (Basel)*. 2023 Aug 24;11(9):1412. doi: 10.3390/vaccines11091412. PMID: 37766089; PMCID: PMC10537287.
- Clemens, S. A., Weckx, L., Clemens, R., Mendes, A. V., Souza, A. R., Silveira, M. B. *et al.* (2022). Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. *Lancet*, 399(10324): 521–9.
- Collier, D. A., Ferreira, I. A. T. M., Kotagiri, P., Datir, R. P., Lim, E. Y., Touizer, *et al.* (2021). Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. *Nature*, 596(7872), 417–422. <https://doi.org/10.1038/s41586-021-03739-1>

- Cummings, M. J., Baldwin, M. R., Abrams, D., Jacobson, S. D., Meyer, B. J., Balough, E. M. *et al.* (2020). Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet*, 2020;395:1763–1770. *Lancet*, 395(10239): 1763–70.
- Daian e Silva, D. d., & da Fonseca, F. G. (2021). The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis. *Vaccines (Basel)*, 9(10): 1101.
- Fan, Y. J., & Chan, K. H. (2021). Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. *Vaccines (Basel)*, 9(9): 989.
- Fulop, T., Larbi, A., Dupuis, G., Le Page, A., Frost, E. H., Cohen, A. A., Witkowski, J. M., & Franceschi, C. (2018). Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?. *Frontiers in immunology*, 8, 1960. <https://doi.org/10.3389/fimmu.2017.01960>
- Galbadage, T., Peterson, B. M., Awada, J., Buck, A. S., Ramirez, D. A., Wilson, J., & Gunasekera, R. S. (2020). Systematic Review and Meta-Analysis of Sex-Specific COVID-19 Clinical Outcomes. *Frontiers in medicine*, 7, 348. <https://doi.org/10.3389/fmed.2020.00348>
- Griffith, D. M., Sharma, G., Holliday, C. S., Enyia, O. K., Valliere, M., Semlow, A. R., Stewart, E. C., & Blumenthal, R. S. (2020). Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions. *Preventing chronic disease*, 17, E63. <https://doi.org/10.5888/pcd17.200247>
- Grunau, B., Goldfarb, D. M., Asamoah-Boaheng, M., Golding, L., Kirkham, T. L., Demers, P. A. *et al.* (2022). Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals. *JAMA*, 327(3): 279.
- Han, X., Xu, P., & Ye, Q. (2021). Analysis of COVID-19 vaccines: Types, thoughts, and application. *J Clin Lab Anal*, 35(9): e23937.
- Hanson, Q. M., Wilson, K. M., Shen, M., Itkin, Z., Eastman, R. T., Shinn, P. *et al.* (2020). Targeting ACE2–RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay. *ACS Pharmacol Transl Sci*, 3(6): 1352–60.
- Harder, T., Koch, J., Vygen-Bonnet, S., Külper-Schiek, W., Pilic, A., Reda, S. *et al.* (2021). Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. *Euro Surveill*, 26(28): 2100563.
- Hay, K. A., Hanafi, L.A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M. *et al.* (2017). Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy. *Blood*.

- Hong, D., Lee, S., Choi, Y. J., Moon, S., Jang, Y., Cho, Y. M. *et al.* (2021). The age-standardized incidence, mortality, and case fatality rates of COVID-19 in 79 countries: a cross-sectional comparison and their correlations with associated factors. *Epidemiology and health*, 43, e2021061. <https://doi.org/10.4178/epih.e2021061>
- Hui, K. P., Cheung, M. C., Perera, R. A., Ng, K. C., Bui, C. H., Wo, J. C. *et al.* (2020). Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. *Lancet Respir Med*, 8(7): 687–95.
- Hunter, C. A., & Jones, S. A. (2015). IL-6 as a keystone cytokine in health and disease. *Nature immunology*, 16(5), 448–457. <https://doi.org/10.1038/ni.3153>
- Hussain, A., Mahawar, K., Xia, Z., Yang, W., & El-Hasani, S. (2020). Obesity and mortality of COVID-19. Meta-analysis. *Obesity research & clinical practice*, 14(4), 295–300. <https://doi.org/10.1016/j.orcp.2020.07.002> (Retraction published *Obes Res Clin Pract.* 2021 Jan-Feb;15(1):100. doi: 10.1016/j.orcp.2020.12.008.)
- Jiang, Y., Xu, J., Zhou, C., Wu, Z., Zhong, S., Liu, J. *et al.* (2005). Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. *Am J Respir Crit Care Med*; 171: 850–857.
- Jin, J. M., Bai, P., He, W., Wu, F., Liu, X. F., Han, D. M., Liu, S., & Yang, J. K. (2020). Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Frontiers in public health*, 8, 152. <https://doi.org/10.3389/fpubh.2020.00152>
- Johnson AG, Amin AB, Ali AR, Hoots B, Cadwell BL, Arora S, *et al.* (2022). COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without *Booster* Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021. *MMWR. Morbidity and mortality weekly report*, 71(4), 132–138. <https://doi.org/10.15585/mmwr.mm7104e2>
- Jordan, R. E., Adab, P., & Cheng, K. K. (2020). Covid-19: risk factors for severe disease and death. *BMJ (Clinical research ed.)*, 368, m1198. <https://doi.org/10.1136/bmj.m1198>
- Kementerian Kesehatan Republik Indonesia. (2016). Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016 tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016–2019. Jakarta: Kementerian Kesehatan RI.
- Kherabi, Y., Fiolet, T., Rozencwajg, S., Salaün, J. P., & Peiffer-Smadja, N. (2021). COVID-19 vaccine *boosters*: What do we know so far? *Anaesthesia Critical Care & Pain Medicine*, 40(6), 100959. <https://doi.org/10.1016/j.accpm.2021.100959>
- Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., *et al.* (2020). Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*, 182(4): 812-27.

- Kuodi, P., Gorelik, Y., Zayyad, H., Wertheim, O., Wiegler, K. B., Abu Jabal, K., Dror, A. A., Nazzal, S., Glikman, D., & Edelstein, M. (2022). Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. *NPJ vaccines*, 7(1), 101. <https://doi.org/10.1038/s41541-022-00526-5>
- Lin, D. Y., Wheeler, B., Young, H., Holloway, S., Sunny, S. K., Moore, Z. *et al.* (2022). Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. *N Engl J Med*, NEJMoa2117128.
- Lukashev, A. N., & Zamyatnin, A. A. (2016). Viral vectors for gene therapy: current state and clinical perspectives. *Biochemistry*, 81: 700–8.
- Lundstrom, K. (2021). Viral Vectors for COVID-19 Vaccine Development. *Viruses*, 13(2), 317. <https://doi.org/10.3390/v13020317>
- Macchi, J., Herskovitz, J., Senan, A. H., Dutta, D., Nath, B., Oleynikov, M. D. *et al.* (2020). The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. *J Neuroimmune Pharmacol*, 21 : 1–28.
- Mangalmurti, N., & Hunter, C. A. (2020). Cytokine Storms: Understanding COVID-19. *Immunity*, 53: 19-25. <https://doi.org/10.1016/j.immuni.2020.06.017>
- Moghadas, S. M., Vilches, T. N., Zhang, K., Wells, C. R., Shoukat, A., Singer, B. H. *et al.* (2021). The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. *Clin Infect Dis*, 73(12): 2257-64.
- Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M. *et al.* (2020). Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. *Cell*, 181(4): 905-13.
- Kang, I. S., & Kong, K. A. (2021). Body mass index and severity/fatality from coronavirus disease 2019: A nationwide epidemiological study in Korea. *PLOS ONE*, 16(6), e0253640. <https://doi.org/10.1371/journal.pone.0253640>
- Al Kaabi, N., Zhang, Y., Xia, S., Yang, Y., Al Qahtani, M.M., Abdulrazzaq, N., Al Nusair, M., *et al.* (2021). Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. *JAMA. American Medical Association*. 326(1):35.
- Munro, A. P., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D. *et al.* (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (*booster*) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet*, 398(10318): 2258-76.
- Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S. *et al.* (2021). Post-acute COVID-19 syndrome. *Nat Med*, 27(4): 601-15.
- Paludan, S. R., & Mogensen, T. H. (2022). Innate immunological pathways in COVID-19 pathogenesis. *Science immunology*, 7(67), eabm5505. <https://doi.org/10.1126/sciimmunol.abm5505>

- Parasher, A. (2021). COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. *Postgraduate Medical Journal*, 97(1147), 312–320. <https://doi.org/10.1136/postgradmedj-2020-138577>
- Payne, R. P., Longet, S., Austin, J. A., Skelly, D. T., Dejnirattisai, W., Adele, S. *et al.* (2021). Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell*, 184(23): 5699.
- Peckham, H., de Gruijter, N. M., Raine, C., Radziszewska, A., Ciurtin, C., Wedderburn, L. R., *et al.* (2020). Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. *Nature Communications*, 11(1), 6317. <https://doi.org/10.1038/s41467-020-19741-6>
- Pietrobon, A. J., Teixeira, F. M. E., & Sato, M. N. (2020). Immunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People. *Frontiers in immunology*, 11, 579220. <https://doi.org/10.3389/fimmu.2020.579220>
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, *et al.* (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *The New England journal of medicine*, 383(27), 2603–2615. <https://doi.org/10.1056/NEJMoa2034577>
- Popkin, B. M., Du, S., Green, W. D., Beck, M. A., Algaith, T., Herbst, C. H., *et al.* (2020). Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. *Obesity Reviews*, 21(11), e13128. <https://doi.org/10.1111/obr.13128>
- Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M. *et al.* (2021). Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination. *Nature*, 600(7890), 701–706. <https://doi.org/10.1038/s41586-021-04120-y>
- Rummel, C., Sachot, C., Poole, S., & Luheshi, G.N. (2006). Circulating interleukin-6 induces fever through a STAT3-linked activation of COX-2 in the brain. *Am J Physiol Regul Integr Comp Physiol*. 291:R1316–R1326.
- Sahin, U., Muik, A., Dehovanessian, E., Vogler, I., Kranz, L.M., Vormehr, M. *et al.* (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature* 586, 594–599.
- Sayedahmed, E. E., Elkashif, A., Alhashimi, M., Sambhara, S., & Mittal, S. K. (2020). Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines. *Vaccines*, 8(4), 574. <https://doi.org/10.3390/vaccines8040574>
- Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C., & Klein, S. L. (2020). Considering how biological sex impacts immune responses and COVID-19 outcomes. *Nature reviews. Immunology*, 20(7), 442–447. <https://doi.org/10.1038/s41577-020-0348-8>
- Sette, A., & Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*, 184(4), 861–880. <https://doi.org/10.1016/j.cell.2021.01.007>

- Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Herikurniawan, H., *et al.* (2020). Coronavirus disease 2019: Review of current literatures. *Jurnal Penyakit Dalam Indonesia*, 7(1), Article 8. <https://doi.org/10.7454/jpdi.v7i1.415>
- Takahashi, T., Ellingson, M.K., Wong, P., Israelow, B., Lucas, C., Klein, J., *et al.* (2020). Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes. *Nature*, 588, 315–320. <https://doi.org/10.1038/s41586-020-2700-3>
- Tanaka T, Narazaki M, Kishimoto T. (2016). Immunotherapeutic implications of IL-6 blockade for cytokine storm. *Immunotherapy*. 8(8):959-70.
- Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N. *et al.* (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet*, 398(10309): 1407-16.
- Teijaro, J.R. and Farber, D.L. (2021). COVID-19 vaccines: modes of immune activation and future challenges. *Nature Reviews Immunology*, Springer US. 21(4):195–197.
- Tenforde, Mark W., Self, Wesley H., Adams, Katherine, Gaglani, Manjusha, Ginde, Adit A. *et al.* (2021). Association between mRNA vaccination and COVID-19 hospitalization and disease severity. *JAMA*, 326(20), 2043–2054. <https://doi.org/10.1001/jama.2021.19499>
- Troiano, G. & Nardi, A. (2021). Vaccine hesitancy in the era of COVID-19. *Public Health*, 194: 245-51.
- Ura, T., Yamashita, A., Mizuki, N., Okuda, K., & Shimada, M. (2021). New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. *Vaccine*, 39(2): 197–201.
- Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., *et al.* Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis*. 2020;20(6):669–677.
- Widge, A.T., Rouphael, N.G., Jackson, L.A., Anderson, E.J., Roberets, P.C., Makhene, M. *et al.* (2021). Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. *N. Engl. J. Med.* 384, 80–82.
- Wu, D., & Yang, X.O. (2020.) TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. *J Microbiol Immunol Infect.* Epub ahead of print 11 March 2020.
- Wu, D., Rao, Q., & Zhang, W. (2021). The natural course of COVID-19 patients without clinical intervention. *J Med Virol*, 93(9): 5527-37.
- Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C. *et al.* (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*; 8: 420–422. [In Press].
- Yanez, N.D., Weiss, N.S., Romand, JA. *et al.* COVID-19 mortality risk for older men and women. *BMC Public Health* 20, 1742 (2020). <https://doi.org/10.1186/s12889-020-09826-8>

- Yang, Z., Jiang, Y., Li F., Liu, D., Lin, T.F., *et al.*, (2023). Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. *The Lancet Microbe*. 4(4): 236–246.
- Yao, Y., Jeyanathan, M., Haddadi, S., Barra, N.G., Damjanovic, D., Lai, R. *et al.* (2018) Induction of autonomous memory alveolar macrophages requires t cell help and is critical to trained immunity. *Cell* 175, 1634–1650.
- Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020). COVID-19 pathophysiology: a review. *Clin Immunol*, 215: 108427.
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z. *et al.* (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*, 395: 1054–62.